Longboard Pharmaceuticals, Inc.

NasdaqGM:LBPH Stock Report

Market Cap: US$2.3b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Longboard Pharmaceuticals Management

Management criteria checks 3/4

Longboard Pharmaceuticals' CEO is Kevin Lind, appointed in Mar 2020, has a tenure of 4.75 years. total yearly compensation is $2.05M, comprised of 29.7% salary and 70.3% bonuses, including company stock and options. directly owns 0.93% of the company’s shares, worth $21.82M. The average tenure of the management team and the board of directors is 3.9 years and 4 years respectively.

Key information

Kevin Lind

Chief executive officer

US$2.1m

Total compensation

CEO salary percentage29.70%
CEO tenure4.8yrs
CEO ownership0.9%
Management average tenure3.9yrs
Board average tenure4yrs

Recent management updates

Recent updates

Seeking Alpha • Oct 15

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management

Summary Longboard Pharmaceuticals is being acquired by Lundbeck for $60 per share, valuing the deal at $2.6 billion, driven by the potential of bexicaserin. Bexicaserin shows promising seizure reduction data, but faces competition and safety concerns; Lundbeck aims for a 2028 launch with peak sales potential of $1.5-$2 billion. Longboard's management, led by CEO Kevin Lind, has a strong track record in securing lucrative M&A deals, making them a team to watch. Investing in Longboard shares now holds little value post-agreement; future opportunities may arise from Lind's next ventures or new spinouts. Read the full article on Seeking Alpha
Seeking Alpha • Aug 28

My Strategy For Longboard Pharmaceuticals After Its Big Run

Summary Longboard Pharma saw significant growth after the initial spike, with potential catalysts in the future. LBPH develops neurological medicines, with a strong pedigree from Arena Pharmaceuticals. Lead drug Bexicaserin has shown promising data, with upcoming catalysts and potential for sustained response. Read the full article on Seeking Alpha
Analysis Article • Jul 12

We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Mar 16

Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely

Summary Longboard Pharmaceuticals has seen a significant increase in its stock price following positive data from its Phase 1b/2a study of bexicaserin, a treatment for developmental and epileptic encephalopathies. The company plans to initiate a Phase 3 study of bexicaserin and hopes to release data from an open-label extension study later this year. Longboard's financials show increased R&D and G&A expenses, but with a potential approval for bexicaserin in play, the company's market cap has risen to over $725m. After a >300% gain in the stock price in recent months, I am not sure there are enough catalysts in play to support further upside in 2024, although the company's second lead candidate, the S1P modulator LP659, is worth keeping an eye on. Read the full article on Seeking Alpha
Analysis Article • Oct 03

Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Dec 25

We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Sep 10

Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • May 28

We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Feb 11

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Oct 27

Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jun 12

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO Compensation Analysis

How has Kevin Lind's remuneration changed compared to Longboard Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$76m

Jun 30 2024n/an/a

-US$65m

Mar 31 2024n/an/a

-US$58m

Dec 31 2023US$2mUS$610k

-US$54m

Sep 30 2023n/an/a

-US$51m

Jun 30 2023n/an/a

-US$49m

Mar 31 2023n/an/a

-US$46m

Dec 31 2022US$2mUS$572k

-US$44m

Sep 30 2022n/an/a

-US$41m

Jun 30 2022n/an/a

-US$36m

Mar 31 2022n/an/a

-US$32m

Dec 31 2021US$875kUS$547k

-US$28m

Sep 30 2021n/an/a

-US$29m

Jun 30 2021n/an/a

-US$25m

Mar 31 2021n/an/a

-US$20m

Dec 31 2020US$2mUS$332k

-US$14m

Compensation vs Market: Kevin's total compensation ($USD2.05M) is below average for companies of similar size in the US market ($USD5.40M).

Compensation vs Earnings: Kevin's compensation has increased whilst the company is unprofitable.

CEO

Kevin Lind (48 yo)

4.8yrs
Tenure
US$2,053,804
Compensation

Mr. Kevin R. Lind serves as President and Chief Executive Officer at Longboard Pharmaceuticals, Inc. since March 2020 and also serves as its director since January 2020. He serves as Director at Ceek Women...

Leadership Team

NamePositionTenureCompensationOwnership
Kevin Lind
President4.8yrsUS$2.05m0.93%
$ 21.8m
Brandi Roberts
Executive VP & CFO3.9yrsUS$1.03m0%
$ 0
Randall Kaye
Executive VP & Chief Medical Officer2.8yrsUS$1.16m0.12%
$ 2.9m
Chadwick Orevillo
Executive VP & Head of Operationsno datano datano data
Steven Spector
Executive VP3.9yrsno datano data
3.9yrs
Average Tenure
54.5yo
Average Age

Experienced Management: LBPH's management team is considered experienced (3.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Kevin Lind
President4.9yrsUS$2.05m0.93%
$ 21.8m
Phillip Schneider
Independent Director4yrsUS$121.80k0%
$ 0
Casey Lynch
Independent Director3.8yrsUS$112.80k0%
$ 0
Paul Sekhri
Independent Chairman of the Board4yrsUS$145.81k0%
$ 0
Vincent Aurentz
Independent Director4.8yrsUS$109.34k0%
$ 0
Corinne Le Goff
Independent Director3.8yrsUS$114.81k0%
$ 0
4.0yrs
Average Tenure
57.5yo
Average Age

Experienced Board: LBPH's board of directors are considered experienced (4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/02 17:06
End of Day Share Price 2024/11/29 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Longboard Pharmaceuticals, Inc. is covered by 2 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Neena Bitritto-GargCitigroup Inc
Yatin SunejaGuggenheim Securities, LLC